These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Sawyer N; Newstead C; Drummond A; Cunningham J Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615 [TBL] [Abstract][Full Text] [Related]
3. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy. Yates AJ; Murray RM; Jerums GJ; Martin TJ Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316 [TBL] [Abstract][Full Text] [Related]
4. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy. Davis JR; Heath DA Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920 [TBL] [Abstract][Full Text] [Related]
5. A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia. Gallacher SJ; Ralston SH; Fraser WD; Dryburgh FJ; Cowan RA; Logue FC; Boyle IT Bone Miner; 1991 Dec; 15(3):249-56. PubMed ID: 1773137 [TBL] [Abstract][Full Text] [Related]
6. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. Davenport A; Goel S; Mackenzie JC Scand J Urol Nephrol; 1993; 27(4):447-51. PubMed ID: 8159916 [TBL] [Abstract][Full Text] [Related]
7. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial. Thürlimann B; Waldburger R; Senn HJ; Thiébaud D Ann Oncol; 1992 Sep; 3(8):619-23. PubMed ID: 1450043 [TBL] [Abstract][Full Text] [Related]
9. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925 [TBL] [Abstract][Full Text] [Related]
10. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. Thiébaud D; Jacquet AF; Burckhardt P Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097 [TBL] [Abstract][Full Text] [Related]
11. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484 [TBL] [Abstract][Full Text] [Related]
12. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. Wimalawansa SJ Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347 [TBL] [Abstract][Full Text] [Related]
13. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. Body JJ; Dumon JC Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034 [TBL] [Abstract][Full Text] [Related]
14. Treatment of tumor-induced osteolysis by APD. Burckhardt P; Thiébaud D; Perey L; von Fliedner V Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665 [TBL] [Abstract][Full Text] [Related]
15. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Gucalp R; Theriault R; Gill I; Madajewicz S; Chapman R; Navari R; Ahmann F; Zelenakas K; Heffernan M; Knight RD Arch Intern Med; 1994 Sep; 154(17):1935-44. PubMed ID: 8074597 [TBL] [Abstract][Full Text] [Related]
16. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Jansson S; Tisell LE; Lindstedt G; Lundberg PA Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370 [TBL] [Abstract][Full Text] [Related]
17. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate. Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202 [TBL] [Abstract][Full Text] [Related]
18. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy. Gurney H; Kefford R; Stuart-Harris R Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054 [TBL] [Abstract][Full Text] [Related]
19. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. Gucalp R; Ritch P; Wiernik PH; Sarma PR; Keller A; Richman SP; Tauer K; Neidhart J; Mallette LE; Siegel R J Clin Oncol; 1992 Jan; 10(1):134-42. PubMed ID: 1727915 [TBL] [Abstract][Full Text] [Related]
20. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy. Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]